Abaxis (ABAX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2016
October 27, 2015 4:01 PM EDTUNION CITY, Calif., Oct. 27, 2015 /PRNewswire/ --Â Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the second fiscal quarter ended September 30, 2015.
Second quarter overview:
Revenues from continuing operations of $56.0 million, up 11% over last year's comparable quarter. Diluted EPS from continuing operations of $0.34, up 36% over last year's comparable quarter. Diluted EPS, including discontinued operations, of $0.34, up 42% over last year's comparable quarter.Revenues highlights:
North... More


